ArticleViruses2026
Weekly HBsAg Decline Dynamics During Combination Therapy with Interferon and Nucleos(t)ide Analogs: A Retrospective Real-World Study.
Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) loss, remains a major goal in chronic hepatitis B (CHB) management. HBsAg kinetics during interferon (IFN)-based therapy are associated with treatment response and prognosis, but real-world data on weekly HBsAg dynamics remain limited. This retrospective real-world study enrolled 533 CHB patients treated with IFN monotherapy or IFN plus tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV). Weekly HBsAg levels up to week 24 were analyzed using propensity score matching (PSM), subgroup analyses, and generalized estimating equations (GEEs). HBsAg kinetics showed marked heterogeneity, with some patients exhibiting transient early increases. Lower baseline HBsAg levels and rapid early decline were strongly associated with HBsAg loss. After PSM, IFN monotherapy and combination therapy showed comparable HBsAg decline trajectories. The three NA regimens demonstrated similar overall kinetics, although subgroup differences were observed by sex, immune activity, HBV DNA status, and prior treatment. TDF showed a faster decline in females, whereas ETV declined faster in males and immune-active patients. In conclusion, HBsAg kinetics during IFN-based therapy are highly heterogeneous and mainly influenced by baseline HBsAg levels, early on-treatment decline, and host factors. Weekly HBsAg monitoring may help predict treatment response and guide individualized CHB management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.